Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors

US9631024B2 · kind B2 · utility

Assignee

• Bionomics Limited · AU

Inventors

• Christopher L. Reyes · Adelaide, AU
• Kristen M. Smith · San Clemente, US
• Peter Chu · Hawthorne, US
• Lioudmila A. Campbell · San Diego, US
• Eric Ailor · San Diego, US

Key dates

• Filing date: Jun 17, 2015
• Grant date: Apr 25, 2017
• Expiry date: Jun 17, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.